Trends in the prevalence of antipsychotic drug use among patients with Alzheimer's disease and other dementias including those treated with antidementia drugs in the community in the UK: a cohort study

Objective To investigate the pattern and trends of use of antipsychotics, antidepressants, hypnotics and anxiolytics in Alzheimer's disease and other dementias and in patients treated with antidementia medications. Design Cohort study with dementia patients formed in the UK Clinical Practice Research Datalink. Participants Patients with incident dementia, between 1995 and 2011 and a reference non-dementia cohort matched on age, gender and date of dementia diagnosis. Two subcohorts included new users of acetylcholinesterase inhibitors (AChEIs) and memantine. The study endpoint was use of antipsychotics, antidepressants, hypnotics and anxiolytics up to 10 years before and 4 years after dementia diagnosis, and for up to 5 years before and 1 year after first use of AChEI or memantine. Results 50 349 patients with incident dementia diagnosis and 50 349 matched controls, 10 794 first-time users of AChEI and 669 of memantine. The mean prevalence of antipsychotic use from 1995 to 2011 on diagnosis of dementia was 12.5%, decreasing from 19.9% in 1995 to 7.4% in 2011. There was an increase in antidepressant use (10.7–26.3%) and a small increase in anxiolytic use. The matched cohort showed a lower use of antipsychotics and anxiolytics but a rise in antidepressants (5.9–13.4%). Both groups showed a decrease in hypnotic use. 10.6% of AChEI and 26.3% of memantine users were prescribed antipsychotics, 34.1% and 26.3% antidepressants, 13.2% and 4.1% anxiolytics and 18.4% and 8.3% hypnotics. The slopes for monthly use of antipsychotics were positive in the year leading up to AChEI and memantine use; after treatment initiation the slope for AChEI users continued to increase but at a reduced rate whereas antipsychotic use declined for memantine users. Conclusions The marked reduction in antipsychotic use in dementia is to be welcomed while there was a steady increase in antidepressant use. There was a decline in antipsychotic use after the initiation of memantine.

[1]  G. Livingston,et al.  Efficacy of Memantine for Agitation in Alzheimer’s Dementia: A Randomised Double-Blind Placebo Controlled Trial , 2012, PloS one.

[2]  Martin Knapp,et al.  Donepezil and memantine for moderate-to-severe Alzheimer's disease. , 2012, The New England journal of medicine.

[3]  J. Hippisley-Cox,et al.  Antidepressant use and risk of adverse outcomes in older people: population based cohort study , 2011, BMJ : British Medical Journal.

[4]  P. Rochon,et al.  Antidepressants for agitation and psychosis in dementia. , 2011, The Cochrane database of systematic reviews.

[5]  L. Schneider,et al.  Trends in antipsychotic use in dementia 1999-2007. , 2011, Archives of general psychiatry.

[6]  C. Lyketsos,et al.  Management of agitation and aggression associated with Alzheimer disease , 2009, Nature Reviews Neurology.

[7]  C. Ballard,et al.  The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial , 2009, The Lancet Neurology.

[8]  F. Pasquier,et al.  Evaluation of the Impact of Memantine Treatment Initiation on Psychotropics Use: A Study from the French National Health Care Database , 2008, Neuroepidemiology.

[9]  J. Georges,et al.  Alzheimer's disease in real life – the dementia carer's survey , 2008, International journal of geriatric psychiatry.

[10]  S. Gauthier,et al.  Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis , 2008, International journal of geriatric psychiatry.

[11]  C. Ballard,et al.  Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. , 2008, The Journal of clinical psychiatry.

[12]  Peter Short,et al.  Connecting for health. , 2008, The British journal of general practice : the journal of the Royal College of General Practitioners.

[13]  Constantine G Lyketsos,et al.  Point and 5‐year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study , 2008, International journal of geriatric psychiatry.

[14]  Martin Knapp,et al.  Donepezil for the treatment of agitation in Alzheimer's disease. , 2007, The New England journal of medicine.

[15]  Stephen Humphreys,et al.  Connecting for health. , 2007, The British journal of general practice : the journal of the Royal College of General Practitioners.

[16]  Daniel Weintraub,et al.  Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. , 2006, The New England journal of medicine.

[17]  Philip S. Insel,et al.  Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. , 2006, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[18]  J. Avorn,et al.  Risk of death in elderly users of conventional vs. atypical antipsychotic medications. , 2005, The New England journal of medicine.

[19]  Lon S Schneider,et al.  Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. , 2005, JAMA.

[20]  David Craig,et al.  A cross-sectional study of neuropsychiatric symptoms in 435 patients with Alzheimer's disease. , 2005, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[21]  D. Craig,et al.  The future of memory clinics , 2004 .

[22]  P. Modrego,et al.  Depression in patients with mild cognitive impairment increases the risk of developing dementia of Alzheimer type: a prospective cohort study. , 2004, Archives of neurology.

[23]  C. Holmes,et al.  The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease , 2004, Neurology.

[24]  Kristine Yaffe,et al.  Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. , 2003, JAMA.

[25]  C. Lyketsos,et al.  Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. , 2002, JAMA.

[26]  A K Wagner,et al.  Segmented regression analysis of interrupted time series studies in medication use research , 2002, Journal of clinical pharmacy and therapeutics.

[27]  Kristine Yaffe,et al.  Patient and caregiver characteristics and nursing home placement in patients with dementia. , 2002, JAMA.

[28]  G A Chase,et al.  Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. , 1990, The American journal of psychiatry.

[29]  Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease , 2010 .

[30]  F. Sherriff,et al.  Memantine for dementia. , 2005, The Cochrane database of systematic reviews.